Drug Profile
GSK 189254
Alternative Names: 189254; GSK-189254; GSK-189254ALatest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antidementias; Benzazepines; Small molecules
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Narcolepsy
Most Recent Events
- 19 Apr 2011 No development reported - Phase-II for Narcolepsy in Europe (PO)
- 21 Jul 2006 Data presented at the 10th International Conference on Alzheimer's Disease and Related Disorders (ICAD-2006) have been added to the Alzheimers pharmacodynamics section
- 14 Feb 2005 Phase-I clinical trials in Dementia in United Kingdom (PO)